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Background: Optimal therapy for patients with unresectable locally advanced extrahepatic cholangiocarcinoma
(ULAC) remains controversial. We analysed the role of radiotherapy in the management of such tumors.
Methods: We retrospectively reviewed the charts of patients treated in our institution with conformal-3D
external-beam-radiotherapy (EBRT) with or without concurrent chemotherapy.
Results: Thirty patients were included: 24 with a primary tumor (group 1) and 6 with a local relapse (group 2).
Toxicity was low. Among 25 patients assessable for EBRT response, we observed 9 complete responses, 4 partial
responses, 10 stabilisations, and 2 progressions. The median follow-up was 12 months. Twenty out of 30 patients
(66%) experienced a relapse, which was metastatic in 75% of cases in the whole series, 87% in group 1, 60% in
group 2 (p = 0.25). Twenty-eight patients (93%) died of relapse or disease complications. Median overall survivals in
the whole group and in group 1 or 2 were respectively 12, 11 and 21 months (p = 0.11). The 1-year and 3-year
progression-free survivals were respectively 38% and 16% in the whole series; 31% and 11% in group 1, 67% and
33% in group 2 (p = 0.35).
Conclusion: EBRT seems efficient to treat ULAC, with acceptable toxicity. For primary disease, the high rate of
metastatic relapse suggests to limit EBRT to non-progressive patients after induction chemotherapy.
Keywords: Inoperable cholangiocarcinoma, Radiotherapy, Chemotherapy, OutcomeBackground
Extrahepatic cholangiocarcinoma (EHCC) is an uncommon
cancer comprising almost 3% of all gastrointestinal
carcinomas and accounting for 4000 new cases diagnosed
each year in France [1]. Most of patients are diagnosed
with locally advanced or metastatic disease with 5-year
overall survival rates of less than 10% [2,3]. To date, there
is no curative therapy apart surgery, but unfortunately
only a minority of tumors are resectable at diagnosis, and
there is no standard therapy for advanced disease. Optimal
therapy for patients with unresectable locally advanced
disease remains controversial. Palliative irradiation fol-
lowing biliary decompression can prolong survival,
with median survival rates between 9 and 14 months
[4-7]. In this study, we have retrospectively reviewed
our experience in the EBRT-based management of main* Correspondence: moureaul@ipc.unicancer.fr
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distribution, and reproduction in any mediumduct cholangiocarcinoma in the settings of unresectable
locally advanced primary disease and local relapse after
resection. Our goals were to determine the tolerance of
treatment, the pattern of failure, and the patients’ outcome.Methods
Patients
Between February 1995 and December 2008, 30 patients
with unresectable main duct tract cholangiocarcinoma
were treated with EBRT in our institution (Paoli-Calmettes
Institute, Marseille, France): 24 for a primary tumor (group
1) and 6 for a local relapse occurring in a mean delay
of 16.3 months [range, 12–27] after surgical resection
of the primary tumour (group 2). Extrahepatic cholan-
giocarcinoma was defined by radiologic and endoscopic
studies as arising from the right and/or left hepatic
ducts, the common hepatic duct, and the common bile
duct. Patients with intrahepatic cholangiocarcinoma,
gallbladder carcinomas, as well as patients with metastaticed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Histological confirmation of diagnosis was obtained
for all patients prior to initiation of treatment. The
non-resectability was defined by surgeons and radiologists
as a coeliac invasion, or a mesenteric or hepatic arterial
invasion, or a portal veinous invasion exceeding 180°
27 patients), and/or non-operability for medical reasons
(3 patients). Patient and tumor characteristics are described
in Table 1. The three patients who presented a T1 or
T2 tumor were treated by exclusive radiation therapy
because they were considered medically non operable.
All data reported in this study have been performed
with the approval of our institutional review board
(“Comité d’Orientation Stratégique, COS”).Table 1 Patients’ and tumor characteristics
All patients (n=30) Locally ad
(n=24)
Age at diagnosis (years) Median (range) 68,3 (46–84) 71,2 (46–8
Gender
Male 19 (63%) 14 (58%)
Female 11 (37%) 10 (42%)
Performance status
0 1 (3%) 1 (4%)
1 21 (70%) 15 (63%)
2 5 (17%) 5 (21%)
3 3 (10%) 3 (12%)
Tumor size (mm) Mean (range) - 36 (12–83)
Location
Hilar - 16 (67%)
Intermediate - 2 (8%)
Distal - 6 (25%)
T (TNM classification)
T1 - 1 (4%)
T2 - 2 (8%)
T3 - 12 (50%)
T4 - 6 (25%)
ND - 3 (13%)
N (TNM classification)
N0 - 11 (46%)
N1 - 11 (46%)
ND - 2 (8%)
Bismuth classification
I - 9 (38%)
III - 4 (16%)
IV - 11 (46%)
Follow-up (months)
Median (range) 61,7 (5–180) 54,8 (5–13
Alive at last follow-up: N 2 2Treatment
Pretreatment biliary drainage was performed in 25 out
of 30 patients, by using endoscopic procedure (n = 23)
or percutaneous transhepatic procedure (n = 2). All patients
received a conformal 3D EBRT, delivered to a median dose
of 48.25 gy [range, 30–78], at standard fractions of 1.8 to 2
Grays, using 6 to 18 MV photons, with all fields treated
five days a week. The clinical target volume (CTV) was
designed to adequately cover the tumour volume (with
at least a 1.5-cm margin) and the primary lymphatic
drainage. The planning target volume encompassed the
CTV with a 1-cm margin in all dimensions. Eighteen
patients (60%) received a concomitant chemotherapy


























Table 3 Grade 3 or 4 toxicity according to treatment
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radiotherapy alone.
Statistical analysis
Toxicity was graded according to the NCI-CTC scale
(CTC v3.0). Tumour response was assessed by CT scan,
using the RECIST 1.0 criteria, 2 months after the end of
radiation therapy. Then, patients were followed-up using
clinical examination, blood sample analysis and CT scan
every 3 months during the 2 first years, then every
6 months. The follow-up was calculated from the date
of diagnosis (primary tumor for group 1 and local
relapse for group 2) to the date of last follow-up. The
progression-free survival (PFS) was defined as the interval
between the date of diagnosis and the date of first relapse
(local and/or metastatic) or death. Local progression-free
survival (LPFS) was defined as the interval between the
date of diagnosis and the date of first local recurrence
or the date of death resulting from any cause. Overall
survival (OS) was defined as the interval between the
date of diagnosis and the date of death resulting from
any cause. Actuarial survival rates were computed
using the Kaplan-Meier method and compared using the
log-rank test [8]. A 3-months landmark analysis was
realized, excluding patients who presented a relapse or
were died before 3 months after the end of the treatment.
To compare the distribution according to categorical
variables, the Fisher’s exact test was used. Univariate
and multivariate analyses for PFS and OS were done
using Cox regression analysis. Univariate analysis tested
the following variables: age, sex, performance status,
patients group, T stage, N stage, Bismuth classification,
tumor size, chemotherapy. Mutivariate analysis was
applied to variables with a p-value inferior to 0.2 in
univariate analysis. A two-sided p-value inferior to 0.05
was considered significant. Statistical analysis was
performed using the survival package (version 2.30)
in the R software (version 2.9.1).
Results
Toxicity
All 30 patients were assessable for toxicity. Eight of
them had no toxicity, among which 3 improved their
performance status during treatment. Acute toxicity
was observed as follows: grade 1 (9 patients), grade 2Table 2 Details of concomitant chemotherapy regimens
Chemotherapy schedules N
Cisplatin (80 mg/m2) d1 + 5 Fluorouracil
(1000 mg/m2/d) d1-d4, weeks 1 and 5
7
Cisplatin (40 mg/m2/week), 5 weeks 4
Carboplatin (AUC 2, bi-weekly), 5 weeks 5
Capecitabine 1600 mg/m2/d, 5 d/week, 5 weeks 2(13 patients), grade 3 (7 patients), and grade 4 (2 patients:
one who presented a major systemic infection, and one a
febrile neutropenia). Details of grade 3 and 4 toxicities
are given in Table 3. Given the small number of patients
exhibiting grade 3–4 toxicity, no statistical analysis
was done. As expected, nausea and vomiting were
more frequent when chemotherapy was associated.
Five out of 30 patients experienced acute cholangitis
during radiotherapy, which was adequately addressed
with stent desobstruction (n = 2) or change (n = 3),
and antibiotics. One patient experienced an ischemic
cerebral accident during treatment. One patient definitively
stopped the treatment because of grade 4 toxicity. No
toxic death was observed.
Radiological response to radiation therapy, pattern of
failure, and clinical outcome
Among the 30 patients, 25 were assessable for the radio-
logical response 2 months after EBRTcompletion (Table 4).
Nine out of 25 patients experienced a complete response,
4 patients a partial response, 10 patients a stable disease,
and 2 patients experienced disease progression. The
objective response rate was 52% and the overall disease
control rate was 92%.
In the whole population, the median follow up was
12 months (range, 1–83). Twenty out of 30 patients (66%)
experienced a disease progression that was metastatic
(15 patients, 50%), local (4 patients, 13%), or both local
and metastatic (1 patient, 3%). Within the 16 patients
who presented distant metastasis, the metastatic site
was peritoneum (n = 10), liver (n = 4), lung (n = 1), and
both liver and bone (n = 1). The 1-year and 3-year PFS
were 38.4 ± 9% and 15.7% ± 7% respectively (Figure 1a);
the median PFS was 9 months (range, 1–11). Twenty-
eight patients (93%) died: 20 died of disease recurrence
(66%), 6 (17%) of complications (detailed below), and 2 of
unknown cause. The 1-year and 3-year OS were 52% ±
9.3% and 15.3% ± 6.9% respectively (Figure 2a). The me-
dian OS was was 12 months (range, 1–15).
In the group 1, the median follow up was 10 months
(range, 1–70). Fifteen out of 24 patients (62.5%) experi-
enced a recurrence, which was metastatic (12 patients,
50%), local (2 patients, 8.5%), and both local and metastaticRadiation therapy
alone (n = 12)
Radio-chemotherapy
(n = 18)
Grade 3 Grade 4 Grade 3 Grade 4
Nausea and vomiting 4 (22%)
Pain 1 (5%)
Fever 1 (8%) 1 (5%)
Asthenia 1 (8%) 1 (5%)
Total 1 (8%) 1 (8%) 6 (32%) 1 (5%)







Complete response 9 8 1
Partial response 4 3 1
Stable disease 10 6 4
Progressive disease 2 2 0
Not Available 5 5 0
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metastatic relapse, 9 developed a peritoneal carcinosis, 2
developed liver metastasis, one developed lung metastasis,
and one developed both liver and bone metastases. The
1-year and 3-year PFS were 31.1% ± 9.7% and 10.7% ± 6.9%
respectively; the median PFS was 9 months (range, 7–11)
(Figure 1b). Twenty-two patients died: 15 of recurrence
(62.5%), 5 (21%) of complications including sepsis fol-
lowing hepatic abscess (2 patients), infectious ascitis (1
patient), and angiocholitis (2 patients), and 2 of unknown
cause. The 1-year and 3-year OS were 44% ± 10.4% and
10.2% ± 6.7% respectively (Figure 2b). The median OS was
11 months (range, 7–15).
In the group 2, the median follow up was 23 months
(range, 8–83). Five out of 6 patients (83%) experienced
a recurrence: local (2 patients, 33%) and metastatic (3
patients, 50%). The relapse site was metastatic in 3 out
of 5 relapses (2 patients relapsed in the liver and one
patient developed a peritoneal carcinosis). The 1-year
and 3-year PFS were higher than in group 1, but not
significant (p=:0.17, log-rank test): 66.7% ± 19.2% and
33.3% ± 19.2% respectively; the median PFS was 14 months
(range, 0–29) (Figure 1b). All patients died: 5 following
disease recurrence, whereas 1 patient died in complete
remission because of an upper digestive-tract bleeding
(Child C cirrhosis with rupture of oesophageal varices).
Like PFS, the 1-year and 3-year OS were not significantlyFigure 1 Progression-free survival for overall population (Fig 1a), andbetter than in group 1: 83.3% ± 15.2% and 33% ± 19.2%
respectively (Figure 2b). The median OS was was
21 months (range, 5–38) versus 11 in group 1. The 1-
year LPFS was not significantly different between both
groups (75 ± 15.3% in group 1 versus 83.3 ± 15.2% in
group 2; p = 0.67, log-rank test). The results of univar-
iate and multivariate analyses for PFS and OS are
summarized in Table 5. For PFS, both performance status
(PS) and age were significant in univariate analysis, but PS
remained the sole independent factor in multivariate
analysis. For OS, both PS and age were significant in
univariate and multivariate analyses.
Landmark analysis with exclusion of patients who
presented a relapse or died before 23 months after the
end of the treatment was done: median PFS of patients
was 10.5 months [4-17], with 1- and 3-years PFS rates
equal to 50% ± 13.4% and 14.3% ± 9.4% respectively.
Median OS was 13 months [7.5-18.4] and 1- and 3-years
OS rates were 71.4% ± 12.1% and 14.3% ± 9.4% respectively.
Discussion
In this study we evaluated the role of EBRT +/− con-
comitant chemotherapy in patients with extrahepatic
cholangiocarcinoma in the settings of unresectable locally
advanced primary disease and local relapse after resection.
Toxicity was mild to moderate and no toxic death was
observed, suggesting that EBRT can be safely administered
to such patients. The response rate of loco-regional disease
to EBRT and the overall disease control rate were high,
52% and 92% respectively. In literature, the response rate
to EBRT is rarely described, but seems relatively high. For
example, Lu et al. reported a 56% response rate in 18 pa-
tients treated with high-dose radiotherapy [9], and McMas-
ters et al. reported partial (2 patients; 22%) and complete
(3 patients; 33%) pathological response in 9 patients treated
with neoadjuvant chemoradiation [10]. In a series of 35 pa-
tients with unresectable intrahepatic cholangiocarcinoma,according to the group of patients (Fig 1b).
Figure 2 Overall survival for overall population (Fig 2a), and according to the group of patients (Fig 2b).
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overall disease control [11]; Jiang et al. reported a 75% ob-
jective response rate after EBRT for concurrent regional
lymph node metastases in 24 patients with resected intra-
hepatic cholangiocarcinoma [12]. Despite the response
rate, 66% of our patients experienced progression disease.
The first site of disease progression was metastatic, mainly
hepatic and peritoneal, in agreement with recent studies
[5,13]: Ghafoori et al. showed that the majority of patients
with unresectable extra-hepatic disease treated with EBRT
had local control at the time of death with 18 out of 21
disease progressions occurring firstly in metastatic sites
and only 3 in loco-regional sites [5]; similarly, in a German
study [13] including 15 patients treated with primary
chemoradiation, 53% of first treatment failures were
metastatic and 40% were loco-regional. By contrast, the
studies, which have reported a prominence of loco-
regional progressions as first treatment failure, mainly
concern the adjuvant setting [14]. In the study reported by
Ben-David and colleagues, the first site of failure was
locoregional but corresponded in fact to the 28 patients
treated by adjuvant radiotherapy after R0/R1 surgical re-
section [15]. In our series, OS was poor (median
12 months) as previously reported in literature.
Regarding clinical outcome, we differentiated two
populations, those with a locally advanced disease and
those with a local recurrence after curative resection.
These two populations had different clinical outcome after
treatment with RT or RT-CT alone: the first group of pa-
tients treated for a locally advanced primary extrahepatic
cholangiocarcinoma, with a median OS of 11 months, and
a metastatic progression in 87% of patients who relapsed,
and the second group of patients similarly treated for
an unresectable local relapse after primary surgery, with a
median OS of 21 months and 60% of distant failure.
In our study, patients with primary extrahepatic cholan-
giocarcinoma have a poor prognosis, with a high numberof metastatic relapses when the relapse occurs, resulting
in a high disease-related mortality. The survival rates
described here are in accordance with those published
in the literature for unresectable patients treated with
RT or RT-CT [5,9,10,13,15-17] and superior to survival
rates observed with historical controls and symptomatic
palliation. However, this therapeutic strategy has not been
widely adopted for all patients. Considering the frequent
metastatic evolution of such tumors, and the potential
side effects of RT and RT-CT, many patients are treated
with CT alone. Recently, in a phase III randomized study,
patients (most had metastases) treated with CT alone
(gemcitabine and cisplatin) experienced median OS of
11.7 months [18]. Most of the trials investigating the
role of chemotherapy in the management of cholangiocar-
cinomas include patients with locally advanced tumors as
well as those with metastatic disease [19-21]. The survival
rates obtained in our study are in the same range as the
survival rates published for patients treated with RT-CT
alone (9 to 14 months) [4,5,9,10,13,15-17,22,23]. Such a
comparison should be cautiously taken into account,
because data for RT-CT come mainly from old studies
with small sample sizes, longer accrual periods, and
lack of CT scan imaging for staging, as compared with
the CT studies. Furthermore, some patients included in
the CT studies could have benefited from RT-CT after
induction CT and/or second-line therapies.
Anyway, in our series as well as in others published
series, the prognosis of such patients remains poor, with
an important metastatic relapse rate frequently resulting
in rapid disease-related mortality, suggesting the necessity
to integrate new treatment approaches such as systemic
agents [19-21]. For locally advanced pancreatic cancers
(LAPC) patients, primary CT helps to identify those who
may then potentially benefit from RT-CT, therefore
sparing almost 30% of them from this unuseful and
heavy treatment; furthermore, the outcome of patients
Table 5 Univariate (5a) and multivariate analysis (5b) for PFS and OS
PFS OS
n risk n events 1 year-PFS (%) (± SE) p 1 year-OS (%) (± SE) p
a
PS
0–1 22 21 50 ± 10.7 0.001 63.6 ± 10.3 0.006
2–3 8 7 0 15.6 ± 14.2
Age
≤68 years 15 14 58.2 ± 13.1 0.06 79.4 ± 10.6 0.017
>68 years 15 14 20 ± 10.3 26.7 ± 11.4
Sex
M 19 18 31.8 ± 14.9 0.3 52.6 ± 11.5 0.4
F 11 10 42.1 ± 11.3 60.6 ± 15.4
Group 1 24 22 31.1 ± 9.7 0.17 44 ± 10.4 0.11
Group 2 6 6 66.7 ± 19.2 83.3 ± 15.2
T stage
T1-2 3 2 66.7 ± 27.2 0.2 66.6 ± 27.2 0.25
T3-4 18 17 18.3 ± 9.5 35.9 ± 11.7
N stage
N0 11 9 31.8 ± 14.9 0.8 41.6 ± 15.6 0.7
N1 11 11 27.3 ± 13.4 45.5 ± 15
Bismuth
I-II 9 8 33.3 ± 15.7 0.9 44.4 ± 16.6 0.6
III-IV 15 14 29.3 ± 12.2 43.3 ± 13.3
Tumor size ≤ 36 mm 12 10 27.8 ± 13.6 0.8 36.7 ± 14.6 0.3
>36 mm 9 9 33.3 ± 15.7 55.6 ± 16.6
Chemotherapy 0.15
Yes 18 18 44.4 ± 11.7 0.3 66.7 ± 11.1
No 12 10 28.6 ± 13.8 27.5 ± 13.5
b
PFS OS
factors HR [CI95%] p HR [CI95%] p
PS 0–1 vs 2-3 3.9 [1.4-11.1] 0.01 3.9 [1.4-10.9] 0.01
Age ≤68 years vs >68 years 1.5 [0.56-4] 0.4 4.9 [1.2-18.9] 0.02
Group 1 vs 2 0.7 [0.2-2.3] 0.6 0.8 [0.2-2.] 0.7
Chemotherapy yes vs no _ _ 2.4 [0.7-8.2] 0.16
Abbreviations: PS, performance status; SE standard error; T stage and N stage according to TNM classification; Bismuth: Bismuth classification; vs: versus; CI 95%:
95% Confidence interval.
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of induction CT seems better if subsequent RT-CT is
administered as compared with continuation of CT
[24]. This therapeutic strategy, currently widely adopted
in the management of LAPC and tested in a large ran-
domized trial (LAP 07), could be applied to the manage-
ment of unresectable main bile duct cholangiocarcinoma,
which presents almost the same natural history, with a
high and rapid metastatic potential. RT or RT-CT could
be reserved to non-progressive patients after inductionCT in order to increase the local control. In our study,
with the use of a landmark analysis, with the exclusion
of early relapse, we did not observe any difference in
terms of overall survival, which does not support this
hypothesis but the small effective of our study does not
allow drawing any definitive conclusion. In this study,
RT with or without concomitant CT seems efficient to
ensure local control, with 79% of local controls observed
at 1 year for such advanced disease, similar to published
rates in the literature [5]. The optimal radiation dose in
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unknown, but some authors recommend dose level over
45 to 50 Gy in 5 weeks [25,26]. Since larger volumes
will not tolerate a higher dose administrated with external
beam irradiation, internal irradiation with iridium-192
seems to be an attractive approach to boost the area
where more tumor burden exists [27-30]. More recently,
stereotactic fractionated radiotherapy was shown promising
to increase the rate of local control [31]. The role of
CT in combination with RT remains undefined. The
use of 5FU-based CT in combination with RT is extrapo-
lated from the survival benefit demonstrated with other
gastrointestinal malignancies, including pancreatic cancer
[32-34]. The number of patients reported to be receiving
combined therapy is too small to draw conclusions about
the benefit of concomitant CT, with reports showing
conflicting results [5,22,35,36]. In our study, RT-CT
was well tolerated with an acceptable incidence of acute
side effects, not very different from patients treated by
exclusive RT. Based on the lack of significant toxicity
added with CT in published series, and the proven benefit
of this treatment in other gastrointestinal malignancies,
the use of concomitant RT-CT can be recommended in
biliary tract cancers [23].
However, our second group of patients, treated by RT
for an unresectable local relapse of disease after primary
surgery, experienced better outcome, with a median OS
of 21 months after RT (+/−CT). The differences in PFS,
OS and site of relapses between the 2 groups 1 and 2,
were not statistically significant, likely because of an
insufficient number of patients, but this difference has
still been reported in the literature, in a small series
where patients treated for a local relapse after primary
surgery had better outcome [25]. Local relapse represents
33% of all relapses of patients treated by primary surgery
for extrahepatic cholangiocarcinomas, most of patients
developing distant metastasis at the time of recurrence
[37]. The median OS described in this study for this
specific group of patients is superior to that described
in series of patients treated by exclusive surgery [7,38].
Even though these results should be cautiously taken
into account because of the small size of this group, they
suggest a potential benefit of such aggressive loco-regional
treatment for this specific selected population. Tumors
initially resectable and who recurred only locally had
certainly a less aggressive behaviour than most of biliary
tract cancers, likely explaining in part the better outcome
when compared to initially locoregional advanced cancers.
These findings are comforted by Yoon and colleagues
who reported two cases of patients treated by curative
reoperation for recurrent cancer of the extrahepatic bile
duct, both alive at 46 and 9 months [39]. The authors
concluded that a surgical curative re-resection is possible
in selected patients with recurrent bile duct cancer, mostlyof the papillary type, and such aggressive treatment should
be considered whenever possible in case of recurrence.
Our study presents some limitations. The first one its
retrospective nature and the small number of patients
included. In fact, this limitation is due to the scarcity
of disease: to our knowledge, all studies reported in
literature [4,5,9,10,13,15-17,22,23] are retrospective and
small, the largest one including 54 patients [17]. No
prospective randomized study is available in literature
regarding the role of radiation therapy in unresectable
patients. The second limitation is the absence of control
group that would include unresectable patients not
treated with radiotherapy. In fact, based on several older
publications for review see [6,7] that suggested that EBRT
offers effective palliation of symptomatic disease and
improves survival, it has been our institutional policy for
more than 10 years to routinely recommend radiotherapy
to patients with unresectable extrahepatic cholangiocarci-
nomas, and the aim of our study was to report our ex-
perience during the conformal 3D RT period between
1995 and 2008. Similarly, most of published retro-
spective studies do not include any control group
[4,5,9,10,13,15-17,22,23].
Conclusion
Despite the retrospective nature of our study, the absence
of control group and the size limitation that of course
limit the statistical power, 3D conformal radiation therapy,
ideally combined with concomitant chemotherapy, seems
to be efficient in the loco-regional management of locally
advanced non-operable extrahepatic cholangiocarcinomas,
with an acceptable tolerance. However, the rate of distant
relapse remains high, suggesting the need to develop
new drugs efficient to treat micrometastatic disease. For
locally advanced disease, concomitant radio-chemotherapy
should not be administrated initially, but should be delayed
after induction chemotherapy and reserved to patients
with non-progressive disease. On the contrary, because
of a better survival observed for patients presenting a
local relapse after primary surgery, concomitant radio-
chemotherapy seems to be a promising treatment for
this group of patients.
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